Research location
Lenasia
Gauteng, South Africa
Advertisement
Research activity in Lenasia
Gauteng, South AfricaCureCurrent currently publishes aggregate city-level research activity for this location: 24 trials and 25 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Lenasia
24 linked trials · page 1 of 1A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.NCT05776927 · 2026-08-04 · 1 site observation
RECRUITING
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 · 2026-05-21 · 1 site observation
RECRUITING
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 DiabetesNCT06340854 · 2024-04-19 · 1 site observation
COMPLETED
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161 · 2024-03-26 · 1 site observation
COMPLETED
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation
TERMINATED
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 · 2022-11-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)NCT05013229 · 2021-11-30 · 1 site observation
COMPLETED
A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical PracticeNCT04042441 · 2019-07-29 · 1 site observation
COMPLETED
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 2 site observations
COMPLETED
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO StudyNCT03687827 · 2018-10-02 · 1 site observation
COMPLETED
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 DiabetesNCT03689374 · 2018-10-01 · 1 site observation
COMPLETED
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 DiabetesNCT02692716 · 2017-01-17 · 1 site observation
COMPLETED
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After RamadanNCT02648217 · 2016-01-04 · 1 site observation
COMPLETED
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal InsulinNCT02131272 · 2014-06-11 · 1 site observation
TERMINATED
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 DiabetesNCT01917656 · 2014-01-09 · 1 site observation
COMPLETED
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular DiseaseNCT01609582 · 2012-06-01 · 1 site observation
TERMINATED
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - DiabetesNCT01272232 · 2011-06-01 · 1 site observation
COMPLETED
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsNCT01179048 · 2010-08-31 · 1 site observation
COMPLETED
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.NCT01098539 · 2010-05-01 · 1 site observation
COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin GlargineNCT00976391 · 2009-09-01 · 1 site observation
COMPLETED
Efficacy and Safety of Albiglutide in Treatment of Type 2 DiabetesNCT00838903 · 2009-02-01 · 1 site observation
COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 DiabetesNCT00838916 · 2009-02-01 · 1 site observation
COMPLETED
Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mgNCT00242775 · 2005-05-01 · 1 site observation
COMPLETED
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD PatientsNCT00206154 · 2005-04-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.